Product Description

🔹 Product Overview
Fuvestrol 250 mg Injection contains Fulvestrant 250 mg, an estrogen receptor antagonist/down regulator used in the treatment of certain hormone receptor-positive breast cancers.
It is supplied as a 5 mL prefilled syringe and is administered by intramuscular injection by a healthcare professional.

🔹 Composition
Active Ingredient: Fulvestrant
Strength: 250 mg/5 mL
Dosage Form: Injection
Route: Intramuscular (IM)
Therapeutic Class: Antineoplastic / Estrogen receptor antagonist
Pack: 5 mL prefilled syringe

🔹 Uses & Indications
Fuvestrol 250 mg may be prescribed for:

Hormone receptor-positive breast cancer
Advanced or metastatic breast cancer in appropriate postmenopausal patients
Breast cancer that has progressed following previous endocrine therapy, according to the oncologist's treatment plan.

🔹 How It Works
Fulvestrant binds to estrogen receptors in breast cancer cells.
It blocks estrogen signaling and promotes degradation of estrogen receptors.
This can reduce the growth of breast cancer cells that depend on estrogen signaling.

🔹 Key Benefits
Provides targeted endocrine therapy for HR-positive breast cancer.
Helps reduce estrogen-receptor signaling in cancer cells.
Available as a long-acting intramuscular formulation.
May be used alone or with other anticancer therapies according to the oncology treatment protocol.

🔹 Administration
Administered deep intramuscularly into the buttocks by a doctor or trained healthcare professional.
The usual fulvestrant schedule involves doses on days 1, 15 and 29, followed by once-monthly administration, although the exact regimen should be determined by the treating oncologist.
Do not self-administer.

🔹 Possible Side Effects
Injection-site pain or reaction
Nausea
Headache
Back pain
Fatigue or weakness
Hot flashes
Bone or joint pain
Decreased appetite
Constipation
Increased liver enzymes

🔹 Precautions
Use only under specialist oncology supervision.
Inform the doctor about liver disease, bleeding disorders, or use of anticoagulant/blood-thinning medicines.
Fulvestrant should generally be avoided during pregnancy because it may harm the developing fetus.
Report unusual bleeding, severe injection-site pain, breathing difficulty, or signs of an allergic reaction.
Store refrigerated at 2–8°C and do not freeze.